BioEngine was recognized as Shanghai "NEW SPECIALIZED" Small and Medium-sized Enterprise" in 2020

Recently, according to the requirements of <Notice on the Release of Shanghai's 2020 "Science and Technology Innovation Action Plan" Shanghai "NEW SPECIALIZED" Small and Medium-sized Enterprise Project Declaration Guide> (Shanghai Science and Technology Guide [2020] No. 22), the assessment of the 2020 Shanghai "NEW SPECIALIZED" Small and Medium-sized Enterprise (including cultivation) was finally completed. The evaluation process includes public independent declaration, review, and recommendation by each district, expert evaluation and public announcement, and validation by the Municipal Science and Technology Commission and the Municipal Economic Information Technology Commission.

As a high-tech enterprise, BioEngine has always attached importance to independent innovation, focusing on the research of animal cell mass culture technology and serum-free culture medium development. The success of the Small and Medium-sized Enterprise is a confirmation of BioEngine's innovation ability, scientific research investment, and independent intellectual property rights, which greatly encourages BioEngine's passion for scientific innovation and R&D excellence.

In the future, BioEngine will make further efforts, continue to increase the investment in R&D innovation, strengthen the introduction and training of scientific and technological talents, further improve the scientific and technological innovation platform system and incentive mechanism, make breakthroughs in the field of key animal cell culture technology, build itself into a leading technology-based technology service enterprise, and promote the development of biopharmaceutical industry.